| pubmed-article:18439876 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18439876 | lifeskim:mentions | umls-concept:C0035235 | lld:lifeskim |
| pubmed-article:18439876 | lifeskim:mentions | umls-concept:C0002351 | lld:lifeskim |
| pubmed-article:18439876 | lifeskim:mentions | umls-concept:C0041904 | lld:lifeskim |
| pubmed-article:18439876 | lifeskim:mentions | umls-concept:C0521117 | lld:lifeskim |
| pubmed-article:18439876 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18439876 | pubmed:dateCreated | 2008-6-20 | lld:pubmed |
| pubmed-article:18439876 | pubmed:abstractText | Respiratory Syncytial Virus (RSV) infection is an important cause of severe infant bronchiolitis, partly due to lower airway inflammation orchestrated by virus-induced chemokine secretion. Chemokine receptors may therefore be therapeutic targets. We investigated RSV-induced chemokine receptor (CCR) 1, 2 and 5 surface expressions in a cellular model and in infants. RSV infection increased human monocytic CCR1, 2 and 5 expression, as assessed by FACS, via replication-dependent mechanisms. CCR1 and CCR5 levels peaked at 36 h and CCR2 levels at 48 h. Monocytes from infants with RSV-bronchiolitis significantly increased CCR1 expression after ex vivo RSV infection compared to controls. Expression of CCR5 also increased, and correlated with CCR1 expression (r=0.78, p<0.0001). CCR1 upregulation correlated with disease severity markers. Monocyte CCR1 receptors were functionally active as stimulation resulted in calcium influx. CCR1/5 blocking strategies may be useful in decreasing cellular inflammation in RSV infection. | lld:pubmed |
| pubmed-article:18439876 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18439876 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18439876 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18439876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18439876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18439876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18439876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18439876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18439876 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18439876 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:18439876 | pubmed:issn | 1521-7035 | lld:pubmed |
| pubmed-article:18439876 | pubmed:author | pubmed-author:FriedlandJon... | lld:pubmed |
| pubmed-article:18439876 | pubmed:author | pubmed-author:MorrisonPaul... | lld:pubmed |
| pubmed-article:18439876 | pubmed:author | pubmed-author:ThomasLynette... | lld:pubmed |
| pubmed-article:18439876 | pubmed:author | pubmed-author:SharlandMikeM | lld:pubmed |
| pubmed-article:18439876 | pubmed:author | pubmed-author:HandforthJenn... | lld:pubmed |
| pubmed-article:18439876 | pubmed:author | pubmed-author:TibbyShaneS | lld:pubmed |
| pubmed-article:18439876 | pubmed:author | pubmed-author:MannaSoumendu... | lld:pubmed |
| pubmed-article:18439876 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18439876 | pubmed:volume | 128 | lld:pubmed |
| pubmed-article:18439876 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18439876 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18439876 | pubmed:pagination | 85-93 | lld:pubmed |
| pubmed-article:18439876 | pubmed:meshHeading | pubmed-meshheading:18439876... | lld:pubmed |
| pubmed-article:18439876 | pubmed:meshHeading | pubmed-meshheading:18439876... | lld:pubmed |
| pubmed-article:18439876 | pubmed:meshHeading | pubmed-meshheading:18439876... | lld:pubmed |
| pubmed-article:18439876 | pubmed:meshHeading | pubmed-meshheading:18439876... | lld:pubmed |
| pubmed-article:18439876 | pubmed:meshHeading | pubmed-meshheading:18439876... | lld:pubmed |
| pubmed-article:18439876 | pubmed:meshHeading | pubmed-meshheading:18439876... | lld:pubmed |
| pubmed-article:18439876 | pubmed:meshHeading | pubmed-meshheading:18439876... | lld:pubmed |
| pubmed-article:18439876 | pubmed:meshHeading | pubmed-meshheading:18439876... | lld:pubmed |
| pubmed-article:18439876 | pubmed:meshHeading | pubmed-meshheading:18439876... | lld:pubmed |
| pubmed-article:18439876 | pubmed:meshHeading | pubmed-meshheading:18439876... | lld:pubmed |
| pubmed-article:18439876 | pubmed:meshHeading | pubmed-meshheading:18439876... | lld:pubmed |
| pubmed-article:18439876 | pubmed:meshHeading | pubmed-meshheading:18439876... | lld:pubmed |
| pubmed-article:18439876 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18439876 | pubmed:articleTitle | Chemokine-receptor upregulation and disease severity in respiratory syncytial virus infection. | lld:pubmed |
| pubmed-article:18439876 | pubmed:affiliation | Department of Infectious Diseases and Immunity, Hammersmith Campus, Imperial College London, UK. | lld:pubmed |
| pubmed-article:18439876 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18439876 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:117029 | entrezgene:pubmed | pubmed-article:18439876 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18439876 | lld:pubmed |
